Elanco Animal Health Incorporated (NYSE:ELAN) Receives $16.71 Average PT from Analysts

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have received an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $16.71.

Several brokerages recently commented on ELAN. The Goldman Sachs Group increased their price objective on shares of Elanco Animal Health from $12.50 to $14.00 and gave the company a “sell” rating in a research report on Tuesday, February 27th. Barclays increased their price objective on shares of Elanco Animal Health from $18.00 to $19.00 and gave the company an “overweight” rating in a research report on Tuesday, February 27th. Morgan Stanley raised their price target on shares of Elanco Animal Health from $16.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, February 27th. Finally, TheStreet raised shares of Elanco Animal Health from a “d+” rating to a “c-” rating in a report on Friday, February 23rd.

Insiders Place Their Bets

In other news, Director R David Hoover bought 20,000 shares of the firm’s stock in a transaction on Wednesday, March 6th. The shares were bought at an average price of $16.14 per share, for a total transaction of $322,800.00. Following the purchase, the director now owns 185,000 shares in the company, valued at $2,985,900. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.57% of the stock is owned by company insiders.

Institutional Investors Weigh In On Elanco Animal Health

Institutional investors and hedge funds have recently modified their holdings of the stock. Jones Financial Companies Lllp bought a new stake in shares of Elanco Animal Health during the fourth quarter valued at approximately $37,000. Tower Research Capital LLC TRC increased its position in Elanco Animal Health by 169.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,212 shares of the company’s stock worth $93,000 after purchasing an additional 3,906 shares during the last quarter. Acadian Asset Management LLC bought a new stake in Elanco Animal Health in the third quarter worth $95,000. C M Bidwell & Associates Ltd. bought a new stake in Elanco Animal Health in the third quarter worth $129,000. Finally, Innovis Asset Management LLC bought a new stake in Elanco Animal Health in the third quarter worth $144,000. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Stock Up 2.0 %

Shares of Elanco Animal Health stock opened at $13.53 on Friday. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.75 and a quick ratio of 1.35. The company has a 50-day moving average of $14.96 and a 200 day moving average of $14.02. The firm has a market cap of $6.68 billion, a price-to-earnings ratio of -5.41, a PEG ratio of 1.42 and a beta of 1.34. Elanco Animal Health has a 1 year low of $7.88 and a 1 year high of $16.88.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Monday, February 26th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.02). Elanco Animal Health had a negative net margin of 27.87% and a positive return on equity of 6.44%. The firm had revenue of $1.04 billion for the quarter, compared to analysts’ expectations of $1 billion. During the same period last year, the company posted $0.19 earnings per share. The business’s revenue for the quarter was up 5.1% compared to the same quarter last year. As a group, sell-side analysts anticipate that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.